MedTrace Logo

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

NCT01536366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.

Conditions

  • Parkinson Disease

Interventions

DRUG

BIA 9-1067

25 mg BIA 9-1067 (single-dose)

DRUG

Repaglinide

0.5 mg repaglinide (single-dose)

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Principal Investigators

  • Manuel Vaz-da-Silva, MD, PhD · BIAL - Portela & Cª S.A.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-07-31
Completion
2011-01-31

Countries

  • Portugal

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01536366 on ClinicalTrials.gov